## Attorney General's Report To The Legislature Concerning The New Jersey False Claims Act Pursuant To <u>N.J.S.A</u>. 2A:32C-18

Calendar Year 2016

- a. The number of cases the Attorney General filed <u>0</u>.
- b. The number of cases private individuals filed <u>95</u>, and for those no longer under seal:
  - (1) The state or federal court in which those cases were filed and the number in each court: State 2 Federal 9
  - (2) The State program or agency involved in each case: Medicaid 9 Other 2
  - (3) Number of cases filed by private individuals who had previously filed a False Claims Act case: <u>1</u>
- c. The amount recovered under the NJFCA in settlement;

Damages	\$ 3,355,819.23
Penalties	\$ 4,096,300.54
Litigation Costs	\$ 0

(1) The cases where the State received a recovery:

<u>Name</u>	Settlement <u>Rec. Date</u>	NJ State Share (inc. relator fee		e State Share Net	NJ Restitution	NJ Penalties <u>&amp; Interest</u>
Millenium Labs	1/4/2016	\$ 127,671.22	16½ \$ 18,954.0	94 \$ 108,717.18 \$	53,361.73	\$ 55,355.45
Novartis	2/2/2016	\$ 2,008,360.29	27 \$ 397,186.	3 \$ 1,611,174.16 \$	640,620.69	\$ 970,553.47
Porter v. Qualitest	2/19/2016	\$ 3,427,245.71	21 \$654,989.			\$1,459,714.52
Alexander v.	5/2/2016	\$ 406,695.65	25 \$ 100,265.			\$ 180,997.80
Warner Chilcott						
Slowick v.	5/9/2016	\$ 761,758.34	16½ \$ 73,842.	80 \$ 687,916.04 \$	338,266.41	\$ 349,649.63
Olympus America						
Doe v. Philips Resp.	6/7/2016	\$ 58,864.68	15¾ \$ 9,271.	9 \$ 49,593.49 \$	49,593.49	\$
Wyeth Pharma.	6/8/2016	\$12,785,888.93	n/a \$	\$12,785,888.93 \$	8,879,089.53	\$3,906,799.40
(Protonix)						
Genentech &	6/15/2016	\$ 184,876.86	17 \$ 18,577.	00 \$ 166,298.96 \$	82,322.49	\$ 83,976.47
OSI/Astellas						
Salix Pharma.	8/18/2016	\$ 974,294.42	19 \$ 184,264.	37 \$ 790,030.05 \$	392,774.06	\$ 397,255.99
N.J.ex rel.Seprotech	9/21/2016	\$ 50,000.00	6 \$ 3,000.	00 \$ 47,000.00 \$	30,000.00*	\$ 17,000.00
Systems v. Metra Industries						
Rahimi v. Zydus	10/6/2016	\$ 10,564.29	25 \$ 2,539.	21 \$ 8,025.08 \$	8,025.08	\$
Walsh v. Ameri-	10/7/2016	\$ 1,420.46	25 \$ 355.	1 \$ 1,065.35 \$	1,065.35	\$
source Bergen (Bellco)						
Omnicare, Inc. (Depakote)	10/26/2016	\$ 552,501.47	15** \$ 4,439.	57 \$ 548,061.90 \$	269,539.79	\$ 278,522.11
Ervin v. Omnicare	10/31/2015	\$ 51,204.26	20 \$ 7,653.	4 \$ 43,551.12 \$	21,683.91	\$ 21,867.21
U.S. ex rel. Martin	12/15/2016	\$ 405,066.67	<u>22</u> \$ 89,114.		•	\$ 285,359.89
v. Para-Plus Translations***						
Totals		<u>\$21,806,413.25</u>	<u>\$1,564,552</u>	<u>.55 \$20,241,960.70 </u>	\$12,234,908.76	\$8,004,051.94

(2) The separate amounts of funds recovered for:

Damages	\$ 3,390,924.23
Penalties	<u>\$ 4,116,606.87</u>
Litigation Costs	\$ O
Total recovered:	\$ 7,507,530.10****

(3) The percentage of the recovery and the amount awarded to the private person who brought the action:

Percentage of the recovery:	Varied per action and per covered conduct period;
	see Relator % in the chart in (1)
Amount:	\$1,563,337.88

<sup>\*</sup>The \$30,000 listed under NJ Restitution in the *N.J. ex rel. Seprotech Systems v. Metra Industries* is for litigation costs. \*\*The amount of the relator's fee listed (\$4,439.57) in *Omnicare Inc. (Depakote)* represents 15% of the portion of the NJ State Share for the time of the covered conduct to which the relator's share applied (10 months out of a 96-month period). \*\*\*Payments in *U.S. ex rel. Martin v. Para-Plus Translations, Inc.* are being made in installments, with a first payment of \$182,862.00 in December 2016 and quarterly payments of approximately \$6,656 for five years, which includes 3.5% interest per year.

<sup>\*\*\*\*</sup>Amounts recovered reflect cases paid in full plus the amounts of installment payments received on a prior year cases (i.e., *Maxim* and *Kesler v. Novartis* (*Bioscrip*)).